About CINV
CINV is one of the most dreaded adverse effects of chemotherapy. It often leads to the postponement or refusal of potentially curative chemotherapy treatment for cancer. This nausea and vomiting, associated with chemotherapy regimen, affects the quality of life of an individual.
The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.
Based on the type of CINV, different treatment regimens are prescribed. The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. Most of the drugs used in the treatment are helpful in the prevention of vomiting but show less effect in treating nausea.
Technavio's analysts forecast the global chemotherapy induced nausea and vomiting drugs market to grow at a CAGR of 4.9% over the period 2014-2019.
Covered in this report
The report covers the present scenario and the growth prospects of the global CINV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies and generics along with the drugs used as off-label for the treatment of CINV.
Technavio's report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• GlaxoSmithKline
• Helsinn
• Heron Therapeutics
• Merck & Co
• Tesaro
Other prominent vendors
• Acacia Pharma
• Aphios
• Barr Laboratories
• Baxter Healthcare
• Eisai
• Especificos Stendhal
• F.Hoffmann La Roche
• Mundipharma
• Mylan Pharmaceuticals
• OPKO Health
• Orchid Healthcare
• Otsuka Pharmaceutical
• ProStrakan
• Sandoz (Novartis)
• Solvay Pharmaceuticals
• Specialised Therapeutics Australia
• Sun Pharma
• Taiho Pharmaceutical
• Teva Pharmaceuticals
Market driver
• Increase in incidence and prevalence of cancer
• For a full, detailed list, view our report
Market challenge
• Complex physiology of CINV
• For a full, detailed list, view our report
Market trend
• Increased use of combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Product profiles
Zofran
Aloxi/Onicit/Paloxi
Akynzeo
Emend
PART 06: Disease Overview
Understanding the disease
Pathophysiology
Types of CINV
Causes
Risk factors
Management
Economic burden
PART 07: Regulatory guidelines on CINV
PART 08: Pipeline analysis
PART 09: Market landscape
Market overview
Market size and forecast
CINV Drugs Market in US
Five forces analysis
PART 10: Market segmentation by ROA
Oral
Parenteral
Transdermal patch
PART 11: Market segmentation by onset of disease in CINV
Acute CINV
Delayed CINV
Anticipatory CINV
Breakthrough CINV
PART 12: Market segmentation by pharmacological class of drugs
5-HT3 Receptor Antagonists
NK-1 Receptor Antagonists
Corticosteroids
Dopamine Receptor Antagonists
Benzodiazepines
Cannabinoids
PART 13: Market segmentation by type of therapy
Monotherapy
Combination therapy
PART 14: Geographical segmentation
PART 15: Market drivers
PART 16: Impact of drivers
PART 17: Market challenges
PART 18: Impact of drivers and challenges
PART 19: Market trends
PART 20: Vendor landscape
Competitive Scenario
Market Share Analysis 2014
Other prominent vendors
PART 21: Key vendor analysis
GlaxoSmithKline
Helsinn
Heron
Merck & Co. Inc.
Tesaro
PART 22: Appendix
List of abbreviation
List of Exhibits:
Exhibit 01: Product offerings
Exhibit 02: Types of CINV
Exhibit 03: Causes of emesis
Exhibit 04: Chemotherapeutic agents related emetic risk
Exhibit 05: Management of CINV
Exhibit 06: Summary of regulatory guidelines by ASCO, ESMO, MASCC, and NCCN for CINV treatment
Exhibit 07: Global CINV drugs market: Pipeline portfolio
Exhibit 08: Global CINV drugs market 2014-2019 ($ millions)
Exhibit 09: CINV drugs market in US 2014-2019 ($ millions)
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global CINV drugs market by ROA
Exhibit 12: Global CINV drugs market segment by onset of disease
Exhibit 13: Global CINV drugs market segment by pharmacological class of drugs
Exhibit 14: Global CINV drugs market segment by type of therapy
Exhibit 15: Segmentation of Global CINV Drugs Market by Geography 2014
Exhibit 16: Drivers of global CINV drugs market
Exhibit 17: Impact of drivers
Exhibit 18: Challenges of global CINV drugs market
Exhibit 19: Impact of drivers and challenges
Exhibit 20: YoY growth and revenue of Emend 2011-2014 ($ millions)
Exhibit 21: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 22: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 24: Helsinn: products
Exhibit 25: Helsinn: Key pipeline products
Exhibit 26: Helsinn: Geographical presence
Exhibit 27: Heron: Product Pipeline
Exhibit 28: Merck & Co. Inc.: Business segmentation by revenue 2013
Exhibit 29: Merck & Co. Inc.: Business segmentation by revenue 2012 and 2013 (US$ billions)
Exhibit 30: Merck & Co. Inc.: Sales by geography 2013
Exhibit 31: Tesaro : Product segmentation
Exhibit 32: Tesaro : Geographical presence
